Child Health 44, 248252
HbA1c Reduction: In the SURPASS-2 trial, Mounjaro (15 mg) achieved a mean HbA1c reduction of 2.07% from baseline at week 40, compared to 1.89% for semaglutide 1 mg
[DOI] [PubMed] [Google Scholar] 19.Sikiric P., Petek M., Seiwerth S., Turkovic B., Grabarevic Z., Rotkvic I., Mise S., Duvnjak M., Udovicic I
The nitric oxide system plays a significant role in BPC-157s effects
reported in approximately 4060% of participants in higher-dose groups Vomiting reported in approximately 2030% of participants at higher doses Diarrhoea Constipation Decreased appetite (which, whilst contributing to weight loss, can also be uncomfortable) The majority of gastrointestinal events were mild to moderate in severity and tended to diminish over time as participants adjusted to the medication
PMID 16766004